8-K: LanzaTech to Spin Out Synthetic Biology Platform into Joint Venture, Appoints Interim CFO

LanzaTech plans to spin out its synthetic biology platform, LanzaX, into a joint venture with Tharsis Capital and appoints Justin Pugh as Interim CFO to focus on cost reductions and SAF opportunities.

Summary

• LanzaTech intends to form LanzaX, a business unit dedicated to its synthetic biology platform, and spin it out as a joint venture with Tharsis Capital.
• The spin-out aims to accelerate project development and allow LanzaTech to focus on its core biorefining operations, including Sustainable Aviation Fuels (SAF).
• LanzaTech has entered into an agreement with Tharsis Capital to assist with the spin-out and explore investment opportunities for LanzaX.
• LanzaTech will contribute existing synbio contracts and a portfolio of over 100 demonstrated molecules to LanzaX.
• The company expects to reduce its cost structure by approximately $8 million annually due to the transfer of over 30 employees to LanzaX.
• Justin Pugh has been appointed as Interim Chief Financial Officer, succeeding Geoff Trukenbrod.
• Pugh's priorities include implementing strategic cost reductions and reallocating resources to focus on ethanol as a feedstock for SAF production.
• LanzaTech has initiated a search for a permanent CFO.

Sentiment

Score: 7

Explanation: The announcement is generally positive, highlighting strategic moves to improve focus and reduce costs. The joint venture is expected to provide access to capital and accelerate project development. However, forward-looking statements are subject to risks and uncertainties.

Positives

• The LanzaX spin-out is expected to accelerate project development and enable a sharper focus on LanzaTech's core biorefining operations.
• The company anticipates an annual cost reduction of approximately $8 million.
• The joint venture with Tharsis Capital is expected to provide access to necessary capital for LanzaX.
• LanzaTech's existing commercial expertise in scaling ethanol production will be leveraged to scale new molecules quickly.
• Tharsis Capital brings deep experience in chemicals and sustainable technology sectors and will be a valued collaborative partner.

Risks

• The forward-looking statements are subject to risks, uncertainties, and assumptions that could cause actual results to differ materially.
• These risks include timing delays, failure of customers to adopt new technologies, fluctuations in feedstock costs, and unforeseen technical or commercial challenges.

Future Outlook

LanzaTech expects the LanzaX collaboration to amplify progress by leveraging shared goals and resources to foster significant advancements in sustainable chemical production and is focused on accelerating the path to profitable operations.

Management Comments

• Dr. Jennifer Holmgren stated that the collaboration with Tharsis Capital will amplify progress and foster advancements in sustainable chemical production.
• Dr. Holmgren believes Justin Pugh will play a key role in supporting the execution and refinement of LanzaTech's strategy.
• Henri Arif of Tharsis Capital believes the global footprint of gas fermentation assets deployed by LanzaTech, combined with its world-leading team of synthetic biology experts joining LanzaX, will create a commercial launchpad that will set a new benchmark in sustainable chemicals.

Industry Context

This announcement reflects a strategic move by LanzaTech to focus on its core biorefining operations and capitalize on the growing demand for sustainable chemicals and fuels, particularly Sustainable Aviation Fuels (SAF). The spin-out of LanzaX allows for dedicated resources and capital to be allocated to the synthetic biology platform, potentially accelerating the development of new molecules and expanding LanzaTech's market reach.

Comparison to Industry Standards

• LanzaTech's approach of spinning out its synthetic biology platform into a joint venture is relatively unique compared to other companies in the bio-recycling and sustainable chemical space.
• Companies like Amyris and Ginkgo Bioworks focus on in-house development of synthetic biology capabilities, while LanzaTech is seeking to leverage external capital and expertise through the joint venture with Tharsis Capital.
• The stated goal of reducing costs by $8 million annually is a significant target and could improve LanzaTech's financial performance compared to peers.
• The focus on scaling ethanol production and expanding into SAF aligns with industry trends and government initiatives to promote sustainable aviation fuels.

Management Changes

Stakeholder Impact

• Shareholders may benefit from the increased focus and potential for accelerated growth in both the core biorefining business and the LanzaX joint venture.
• Employees of LanzaTech will be impacted by the transfer of over 30 full-time employees to LanzaX.
• Customers may benefit from the accelerated development of new molecules and the expansion of LanzaTech's product offerings.
• Suppliers and creditors may be affected by the changes in LanzaTech's cost structure and strategic direction.

Next Steps

• Complete the spin-out of LanzaX as a joint venture with Tharsis Capital.
• Search for a permanent CFO of the Company.
• Implement strategic cost reductions and reallocate resources to focus on ethanol as a feedstock for SAF production.
• Scale new molecules quickly by leveraging LanzaTech's commercial expertise in scaling ethanol production.

Key Dates